US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease
(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback